当前位置:首页 - 行情中心 - 博迅生物(836504) - 财务分析 - 利润表

博迅生物

(836504)

  

流通市值:3.70亿  总市值:9.78亿
流通股本:1636.77万   总股本:4333.31万

利润表

报告期2024-09-302024-06-302024-03-312023-12-31
公司类型通用通用通用通用
一、营业总收入84,213,151.3255,794,252.823,522,483.19142,272,377.62
营业收入84,213,151.3255,794,252.823,522,483.19142,272,377.62
二、营业总成本77,306,703.952,010,999.5322,172,720.15121,581,189.45
营业成本50,665,299.5733,940,655.3213,173,961.2583,935,216.18
税金及附加679,449.6461,371.48200,684.051,229,316.84
销售费用8,962,364.726,540,675.713,238,347.3412,643,976.4
管理费用12,329,994.048,120,904.624,141,557.7416,581,860.02
研发费用4,685,125.053,018,588.681,584,4687,829,023.6
财务费用-15,529.08-71,196.28-166,298.23-638,203.59
其中:利息费用334,471.08235,133.799,588.99753,761.49
其中:利息收入419,121.55353,574.99268,918.351,414,122.31
加:公允价值变动收益94,605.95103,879.72140,082.08-
加:投资收益1,142,545.97884,365.5334,134.69672,370.82
资产处置收益----1,445.19
资产减值损失(新)-634,223.12-279,498.71-396,491.93-1,118,874
信用减值损失(新)-1,000,828.26-1,253,736.39-755,678.04121,702.31
其他收益3,048,693.741,412,028.58815,347.075,913,893.39
营业利润平衡项目0000
四、营业利润9,557,241.74,650,291.971,487,156.9126,278,835.5
加:营业外收入33,194.32--3,500,000
减:营业外支出425,607.82265,557.0510,107.3836,309.72
利润总额平衡项目0000
五、利润总额9,164,828.24,384,734.921,477,049.5329,742,525.78
减:所得税费用988,934.75499,042.1314,351.663,071,128.73
六、净利润8,175,893.453,885,692.821,162,697.8726,671,397.05
持续经营净利润8,175,893.453,885,692.821,162,697.8726,671,397.05
归属于母公司股东的净利润8,175,893.453,885,692.821,162,697.8726,671,397.05
(一)基本每股收益0.190.090.030.72
(二)稀释每股收益0.190.090.030.72
九、综合收益总额8,175,893.453,885,692.821,162,697.8726,671,397.05
归属于母公司股东的综合收益总额8,175,893.453,885,692.821,162,697.8726,671,397.05
公告日期2024-10-302024-08-212024-04-262024-03-15
审计意见(境内)标准无保留意见
TOP↑